by Nikki Angel
Sarcoma Oncology Center
2811 Wilshire Blvd., Suite 414
Los Angeles, CA 90403
The Sarcoma Oncology Center is offering a new trial for leiomyosarcoma.
Phase 1 trial of CBT-1 in Combination with Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin
ClinicalTrials.gov Identifier: NCT03002805
Many cells throughout our bodies naturally contain on their surface a class of proteins that actively remove toxins from our cells during drug metabolism. Researchers have found that some cancer cells have a higher than normal amount of these proteins on their cell surfaces, allowing cancer cells to remove toxins (chemotherapy) from their cells more quickly. This can lead to drug resistance, as the tumor has developed a way to resist the effects of the drug by quickly removing it from cells before it can take its effect.
Researchers believe that sarcoma patients whose tumors have not previously responded to doxorubicin (a common chemotherapy used in the treatment of sarcoma) may not be responding due to this drug resistance scenario. The drug in this trial blocks those cell surface proteins from being able to transport drugs out of the cancer cells, and may reverse drug resistance to doxorubicin.
For more information on this trial and other trials available at the Sarcoma Oncology Center, please contact Nikki at the above phone number.
For information about clinical trials see https://lmsdr.org/leiomyosarcoma-clinical-trials/